<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>识林 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-03T07:44:35+08:00</updated>
  <subtitle>服务于制药行业企业、机构及人员的知识与管理平台</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【周末杂谈】啥也不能耽误涨价</title>
    <updated>2021-01-03T06:36:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/TWQSC52t9Nk_rGNUj9Omsw</id>
    <link href="https://mp.weixin.qq.com/s/TWQSC52t9Nk_rGNUj9Omsw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞新冠疫苗首获 WHO 紧急使用，英国和印度先后授权阿斯利康疫苗</title>
    <updated>2021-01-02T06:02:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/iIPTPChynPlWZjy4XUqLVw</id>
    <link href="https://mp.weixin.qq.com/s/iIPTPChynPlWZjy4XUqLVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>你好 2021，再见 2020！</title>
    <updated>2021-01-01T06:08:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-01:/s/VNGruLcAJbjpeahOXLE7Rw</id>
    <link href="https://mp.weixin.qq.com/s/VNGruLcAJbjpeahOXLE7Rw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>识林资讯的定位</title>
    <updated>2020-12-31T06:34:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/nuZSjSJwRQ-kFyYTCZwElw</id>
    <link href="https://mp.weixin.qq.com/s/nuZSjSJwRQ-kFyYTCZwElw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 批准首款合成肽胰高血糖素仿制药</title>
    <updated>2020-12-30T06:42:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/idPsr8OaTo2IGBdm_r08XQ</id>
    <link href="https://mp.weixin.qq.com/s/idPsr8OaTo2IGBdm_r08XQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 公布 2021 财年非处方药专论企业付费费率</title>
    <updated>2020-12-30T06:42:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/Af_Of_0pmKk6Tua2waRztA</id>
    <link href="https://mp.weixin.qq.com/s/Af_Of_0pmKk6Tua2waRztA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021 年医疗科技行业的三大关键问题</title>
    <updated>2020-12-29T06:32:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/Bl-uViMkkh0w2UriYcVa1A</id>
    <link href="https://mp.weixin.qq.com/s/Bl-uViMkkh0w2UriYcVa1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>英国药监局公布创新许可途径以加快药品开发</title>
    <updated>2020-12-29T06:32:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/7waI7CwjaE4Aeo502dAe2Q</id>
    <link href="https://mp.weixin.qq.com/s/7waI7CwjaE4Aeo502dAe2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一周回顾：生物制品批签发管理办法，仿制透皮贴剂药学研究指导，核查中心远程非现场检查，欧盟批准首个新冠疫苗，FDA批准埃博拉治疗药</title>
    <updated>2020-12-28T06:38:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/zXlbf6ZQ_3wFl9jdTeHIFA</id>
    <link href="https://mp.weixin.qq.com/s/zXlbf6ZQ_3wFl9jdTeHIFA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 年度生物制药产业的 11 个趋势</title>
    <updated>2020-12-28T06:38:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/-Y-51BIsVQQ2SzqT1RAg_w</id>
    <link href="https://mp.weixin.qq.com/s/-Y-51BIsVQQ2SzqT1RAg_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【质量对话】质量，疫情间被遗忘的角落？</title>
    <updated>2020-12-27T06:37:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-27:/s/8wPcNYOma2D4x-d0PX9b0g</id>
    <link href="https://mp.weixin.qq.com/s/8wPcNYOma2D4x-d0PX9b0g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新冠疫苗加速生产下 CMO 面临的挑战</title>
    <updated>2020-12-26T06:33:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-26:/s/9NqE8zxKfPZXLBHwPdFXWw</id>
    <link href="https://mp.weixin.qq.com/s/9NqE8zxKfPZXLBHwPdFXWw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 对仿制螺内酯新适应症的特殊支持、审评及专家会意见</title>
    <updated>2020-12-25T06:03:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/FXQy02Qm0Ujn_Bjtke51LQ</id>
    <link href="https://mp.weixin.qq.com/s/FXQy02Qm0Ujn_Bjtke51LQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>行业组织要求 FDA 提供更多可互换生物制品指南</title>
    <updated>2020-12-25T06:03:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/5q1FH8z8pAM6xgkFzvHO8g</id>
    <link href="https://mp.weixin.qq.com/s/5q1FH8z8pAM6xgkFzvHO8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>